Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04023071
Title FT516 in Subjects With Advanced Hematologic Malignancies
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Fate Therapeutics
Indications

B-cell lymphoma

acute myeloid leukemia

Therapies

Aldesleukin + Cyclophosphamide + Fludarabine + FT516 + Obinutuzumab

Aldesleukin + Cyclophosphamide + Fludarabine + FT516 + Rituximab

Aldesleukin + Cyclophosphamide + Fludarabine + FT516

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.